What's Macquarie's price target for NIB shares?

Is the broker positive or negative on NIB's shares?

The NIB Holdings Ltd (ASX: NHF) share price has slipped slightly this morning. As of 11 am, shares are trading 0.81% lower at $7.35 a piece.

NIB's share price has jumped 33.1% since January. But thanks to a steep 17.8% plunge in late-August last year, the health insurer's share price is still down 2.26% for the year.

In a recent note to investors, Macquarie Group Ltd (ASX: MQG) revealed what it expects for NIB's share price over the next 12 months.

Private health insurance diagram.

Image source: Getty Images

Macquarie's stance on NIB shares

The broker has confirmed its underperform rating on NIB shares and its target price of $5.60. 

That represents a potential downside of 23.8% for investors over the next 12 months.

"With multiple divisions experiencing operational and environmental headwinds, we retain our cautious outlook," Macquarie said in its note.

Macquarie expects more political and regulatory risk in FY 2026 as the Health Minister takes a second term and government focus on NDIS funding intensifies.

What to keep an eye on

Key catalysts to watch are the government review into phoenixing – where a company is deliberately liquidated to avoid paying debts before being restarted under another name, changes to the price approval process, changes to the student deed, and findings of the PALM (Pacific Australia Labour Mobility scheme) review.

Macquarie notes:

Residents – Payout Ratio: We expect further direction from the Department of Health on #1) phoenixing; #2) look-back mechanism for price approval, and #3) limits to "free periods", to be released over CY25 and impact CY26 results: "Why a claims payout ratio misses the mark" published 13 Jun '25. Worst case: this accounts for ~12.4% of Group UOP by FY27.

It adds that for international workers, even if NIB retains the PALM contract, it is unlikely to retain the high margins it enjoyed previously. At worst, this could account for 2.5% of the group's underlying operating profit or 4%-5% of the group's underlying operating profit with 50% stranded costs. It also said:

International – Students: NHF's costs are below the 12% commission cap so we foresee this change having limited impact. […] Worst case: this accounts for ~2.2% of Group UOP, before stranded costs and potential knock-on for residents.

For NDIS funding, the broker expects earnings declines in the coming 18-24 months as scheme reform remains elusive. In a worst-case scenario, this could account for 4.8% of the group's underlying operating profit. 

Macquarie notes that a new division head has been appointed to NIB New Zealand. This could pose a downside earnings risk as high as 6.6% on the group's underlying operating profit.

Earnings changes: FY25E: +1.8%; FY26E: -3.6%; and -1% to -5% for FY27 to FY29 reflecting above mentioned divisional challenges and MTMs.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group and NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »